Hemotherapy

Division of Hemotherapy

The division of Hemotherapy is headed by Dr. Nelly Carpio, who is responsible for quality assurance and security of blood banking/transfusion medicine, prevention of haemolytic disease of the newborn and apheresis procedures. The main role of this section, apart from giving support to the Haematology service, is providing a Central Service that supports La Fe Hospital and its influence areas.

The division of hemotherapy is divided into three different activities: blood transfusion and immunoHaematology laboratories, apheresis procedures area and blood-saving programme, and the office of quality and hemovigilance.  The division of hemotherapy is considered as a reference laboratory in both the Valencian Community and at national level.

 

  • Blood transfusion laboratory: The Blood transfusion laboratory operates 24 hours a day, seven days a week, being its main role to guarantee a safe transfusion of blood and blood components.
  • ImmunoHaematology laboratory: It is dedicated to the resolution of complex compatibility problems related to transfusions that come up in both the area of transfusion and complex immunohematological studies, which are requested in other areas within the hospital. This area also covers the maternal-fetal studies related to the diagnostic, treatment and prevention of the haemolytic disease of the newborn.
  • Apheresis procedures area: This area is responsible for the execution of therapeutic procedures as well as the collection of cellular products, which covers:  therapeutic plasma products for patients suffering from haematological malignancies such as Immune  thrombocytopenic purpura(ITP), degenerative pathologies related to the central nervous system and other pathologies such as humoral rejection after renal transplantation, therapeutic erythroapheresis in patients suffering from Malaria, leucoapheresis in some specific patients in order to reduce tumour mass, leucoapheresis during allogenic transplantation for immunologic therapy for hematopoietic stem cell transplantation, selective immunoabsortion of the mononuclear layer in patients affected by rheumatic diseases or related chronic inflammatory bowel disease, extraction of haematopoietic progenitors cells for the therapy with hematopoietic autologous stem cell transplantation and for allogenic stem cell transplantation for related and non-related donors  as well as the selection of specific cellular populations from the product obtained by apheresis.
  • Blood-saving programme: This programme offers its service to the patients from programmed surgeries mainly coming from orthopaedic surgery, heart surgery or other programmed interventions which fulfil some specific requirements (age, sex and intervention type). It covers the extraction of autologous blood and the preparation of patients before the surgery. The main objective of this procedure is avoiding allogenic blood transfusion and the drawbacks related to it.
  • Office of Quality and Hemovigilance: The Office of Quality and Hemovigilance covers a set of different activities from the active vigilance of all adverse effects related to the transfusion of blood. The adverse effects can be detected by either our team members or the medical doctors during their transfusion or in follow-up visits, together with those communicated by the CTCV (Centro de Transfusión de la Comunidad Valenciana, Blood Transfusion Center from the Valencian Community)  in order to excluded any potential infectious units, which could be related to the transmission of pathogen agents.

 

The main advantage of the Blood Bank is our commitment to quality. Currently, there are two quality systems in place:

  • CAT (Comité de Acreditación en Transfusión, Blood Transfusion Acreditation Committee) which certifies the blood transfusion quality and the management of the blood-saving programmes.
  • JACIE (Joint Acreditation Committee-ISCT) which certifies the hematopoietic stem cell transplantation and the apheresis procedures area.